Literature DB >> 11500448

Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells.

A George-Chandy1, K Eriksson, M Lebens, I Nordström, E Schön, J Holmgren.   

Abstract

Cholera toxin B subunit (CTB) is an efficient mucosal carrier molecule for the generation of mucosal antibody responses and/or induction of systemic T-cell tolerance to linked antigens. CTB binds with high affinity to GM1 ganglioside cell surface receptors. In this study, we evaluated how conjugation of a peptide or protein antigen to CTB by chemical coupling or genetic fusion influences the T-cell-activating capacity of different antigen-presenting cell (APC) subsets. Using an in vitro system in which antigen-pulsed APCs were incubated with antigen-specific, T-cell receptor-transgenic T cells, we found that the dose of antigen required for T-cell activation could be decreased >10,000-fold using CTB-conjugated compared to free antigen. In contrast, no beneficial effects were observed when CTB was simply admixed with antigen. CTB conjugation enhanced the antigen-presenting capacity not only of dendritic cells and B cells but also of macrophages, which expressed low levels of cell surface major histocompatibility complex (MHC) class II and were normally poor activators of naive T cells. Enhanced antigen-presenting activity by CTB-linked antigen resulted in both increased T-cell proliferation and increased interleukin-12 and gamma interferon secretion and was associated with up-regulation of CD40 and CD86 on the APC surface. These results imply that conjugation to CTB dramatically lowers the threshold concentration of antigen required for immune cell activation and also permits low-MHC II-expressing APCs to prime for a specific immune response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11500448      PMCID: PMC98688          DOI: 10.1128/IAI.69.9.5716-5725.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  54 in total

1.  Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit.

Authors:  J B Sun; C Rask; T Olsson; J Holmgren; C Czerkinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance.

Authors:  J B Sun; J Holmgren; C Czerkinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

3.  Peripheral tolerance of CD4 T cells following local activation in adolescent mice.

Authors:  I Förster; I Lieberam
Journal:  Eur J Immunol       Date:  1996-12       Impact factor: 5.532

4.  Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli.

Authors:  M Bckström; J Holmgren; F Schödel; M Lebens
Journal:  Gene       Date:  1995-11-20       Impact factor: 3.688

Review 5.  The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells.

Authors:  A J McAdam; A N Schweitzer; A H Sharpe
Journal:  Immunol Rev       Date:  1998-10       Impact factor: 12.988

6.  Large-scale production of Vibrio cholerae toxin B subunit for use in oral vaccines.

Authors:  M Lebens; S Johansson; J Osek; M Lindblad; J Holmgren
Journal:  Biotechnology (N Y)       Date:  1993-12

7.  Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates.

Authors:  C Bergquist; T Lagergård; M Lindblad; J Holmgren
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

8.  Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit.

Authors:  M Bäckström; M Lebens; F Schödel; J Holmgren
Journal:  Gene       Date:  1994-11-18       Impact factor: 3.688

9.  Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets.

Authors:  T O Nashar; H M Webb; S Eaglestone; N A Williams; T R Hirst
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

10.  Successful T cell priming in B cell-deficient mice.

Authors:  M M Epstein; F Di Rosa; D Jankovic; A Sher; P Matzinger
Journal:  J Exp Med       Date:  1995-10-01       Impact factor: 14.307

View more
  55 in total

1.  Increased immunogenicity to LipL32 of Leptospira interrogans when expressed as a fusion protein with the cholera toxin B subunit.

Authors:  Alejandra Habarta; Patricia A E Abreu; Noelia Olivera; Pricila Hauk; Maia T Cédola; María F Ferrer; Paulo L Ho; Ricardo M Gomez
Journal:  Curr Microbiol       Date:  2010-08-19       Impact factor: 2.188

2.  An HIV-1 tat-autoantigen fusion protein suppresses insulitis in NOD mice.

Authors:  Tae-Geum Kim; Jie Yu; John Hough; David Henderson; William H R Langridge
Journal:  Mol Biotechnol       Date:  2005-07       Impact factor: 2.695

3.  Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems.

Authors:  Tetsuya Harakuni; Hideki Sugawa; Ai Komesu; Masayuki Tadano; Takeshi Arakawa
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Induction of cell signaling events by the cholera toxin B subunit in antigen-presenting cells.

Authors:  Aletta C Schnitzler; Jennifer M Burke; Lee M Wetzler
Journal:  Infect Immun       Date:  2007-03-12       Impact factor: 3.441

5.  Immunological activation following transcutaneous delivery of HR-gp100 protein.

Authors:  Shoshana Frankenburg; Igor Grinberg; Ziva Bazak; Lena Fingerut; Jacob Pitcovski; Raphael Gorodetsky; Tamar Peretz; Ram M Spira; Yehuda Skornik; Ronald S Goldstein
Journal:  Vaccine       Date:  2007-04-25       Impact factor: 3.641

6.  Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B.

Authors:  Sang-Moo Kang; Qizhi Yao; Lizheng Guo; Richard W Compans
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

7.  Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.

Authors:  Nobuyuki Matoba; Tagan A Griffin; Michele Mittman; Jeffrey D Doran; Annette Alfsen; David C Montefiori; Carl V Hanson; Morgane Bomsel; Tsafrir S Mor
Journal:  Curr HIV Res       Date:  2008-05       Impact factor: 1.581

8.  Gut T cell receptor-γδ(+) intraepithelial lymphocytes are activated selectively by cholera toxin to break oral tolerance in mice.

Authors:  C P Frossard; K E Asigbetse; D Burger; P A Eigenmann
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

Review 9.  Current Developments and Future Prospects for Plant-Made Biopharmaceuticals Against Rabies.

Authors:  Sergio Rosales-Mendoza
Journal:  Mol Biotechnol       Date:  2015-10       Impact factor: 2.695

10.  Mucosal immunization with a Staphylococcus aureus IsdA-cholera toxin A2/B chimera induces antigen-specific Th2-type responses in mice.

Authors:  Britni M Arlian; Juliette K Tinker
Journal:  Clin Vaccine Immunol       Date:  2011-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.